Personal Genome Diagnostics CEO and leadership

Megan joined PGDx in March 2018 as the Vice President of Marketing and was promoted to Chief Commercial Officer where she led the Company’s marketing, sales, customer support, and communications in developing and executing global go-to-market strategies. Currently, as Chief Executive Officer, Megan leads PGDx with her extensive knowledge of clinical diagnostics, along with business development and commercialization. Prior to joining PGDx, Megan served as Senior Director of Commercial Operations, responsible for leading sales teams across Roche’s Clinical Chemistry/Immunoassay, Molecular, Tissue, and Point of Care divisions in the Southeast United States. She also held marketing leadership roles for the Tissue Diagnostics division where she led multiple product launches, developed and executed commercial strategies across a variety of product lines, and drove strategic collaborations with some of the nation’s largest Integrated Health Networks. Megan earned her Bachelor’s from the United States Military Academy at West Point and her Master of Public Health from the University of North Carolina.

Luis Diaz is a Chairman Of The Board and co-Founder at PERSONAL GENOME DIAGNOSTICS; Director at PERSONAL GENOME DIAGNOSTICS; and Head, Division of Solid Tumor Oncology at Memorial Sloan - Kettering Cancer Center and is based in City Metropolitan Area, New York City, New York. He works or has worked at JOHNS HOPKINS UNIVERSITY. Luis studied at University of Michigan between 1989 and 1993, Johns Hopkins University School of Medicine/The between 2001 and 2004, and University of Michigan Medical School between 1994 and 1998.

Dr. Velculescu is internationally known for his discoveries in genomics and cancer research. He and his colleagues performed the first genome-wide sequence analysis in human cancers, identifying key genes and pathways dysregulated in tumorigenesis. He developed methods for global gene expression analyses and coined the word “transcriptome" to describe the patterns that could now obtained in cancer and other cells. These analyses identified a variety of genes not previously known to be involved in neoplasia, including PIK3CA as one of the most highly mutated genes in human cancer. These efforts have led to new FDA approved therapies and diagnostic tests widely used for cancer patients. More recently, his group has developed non-invasive liquid biopsy approaches for early detection and monitoring of cancer patients. These discoveries provide new paradigms for our understanding of human cancer that have benefited patients worldwide.

Luis Diaz is a Chairman Of The Board and co-Founder at PERSONAL GENOME DIAGNOSTICS; Director at PERSONAL GENOME DIAGNOSTICS; and Head, Division of Solid Tumor Oncology at Memorial Sloan - Kettering Cancer Center and is based in City Metropolitan Area, New York City, New York. He works or has worked at JOHNS HOPKINS UNIVERSITY. Luis studied at University of Michigan between 1989 and 1993, Johns Hopkins University School of Medicine/The between 2001 and 2004, and University of Michigan Medical School between 1994 and 1998.

Dr. Velculescu is internationally known for his discoveries in genomics and cancer research. He and his colleagues performed the first genome-wide sequence analysis in human cancers, identifying key genes and pathways dysregulated in tumorigenesis. He developed methods for global gene expression analyses and coined the word “transcriptome" to describe the patterns that could now obtained in cancer and other cells. These analyses identified a variety of genes not previously known to be involved in neoplasia, including PIK3CA as one of the most highly mutated genes in human cancer. These efforts have led to new FDA approved therapies and diagnostic tests widely used for cancer patients. More recently, his group has developed non-invasive liquid biopsy approaches for early detection and monitoring of cancer patients. These discoveries provide new paradigms for our understanding of human cancer that have benefited patients worldwide.

Luis Diaz is a Chairman Of The Board and co-Founder at PERSONAL GENOME DIAGNOSTICS; Director at PERSONAL GENOME DIAGNOSTICS; and Head, Division of Solid Tumor Oncology at Memorial Sloan - Kettering Cancer Center and is based in City Metropolitan Area, New York City, New York. He works or has worked at JOHNS HOPKINS UNIVERSITY. Luis studied at University of Michigan between 1989 and 1993, Johns Hopkins University School of Medicine/The between 2001 and 2004, and University of Michigan Medical School between 1994 and 1998.

Dr. Velculescu is internationally known for his discoveries in genomics and cancer research. He and his colleagues performed the first genome-wide sequence analysis in human cancers, identifying key genes and pathways dysregulated in tumorigenesis. He developed methods for global gene expression analyses and coined the word “transcriptome" to describe the patterns that could now obtained in cancer and other cells. These analyses identified a variety of genes not previously known to be involved in neoplasia, including PIK3CA as one of the most highly mutated genes in human cancer. These efforts have led to new FDA approved therapies and diagnostic tests widely used for cancer patients. More recently, his group has developed non-invasive liquid biopsy approaches for early detection and monitoring of cancer patients. These discoveries provide new paradigms for our understanding of human cancer that have benefited patients worldwide.